News

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Madrigal Pharmaceuticals Shares Rise After Receiving U.S. Patent for Rezdiffra Treatment
Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...
InvestorsHub on MSN3d
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...
Madrigal stock jumps as patent protection for MASH treatment extended
The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...
Taiwan News3d
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...
Healio6d
Resmetirom, glucagon receptor agonists appear similarly effective for MASLD, MASH
In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...